(NEWS) Weight loss medication & yo-yo effect: Meta-analysis shows +0.4 kg/month after stopping medication

GLP-1 agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are considered revolutionary in the treatment of obesity – but what happens after discontinuation? A new meta-analysis in the British Medical Journal (BMJ) of 37 studies with 9,341 participants shows that after stopping weight-loss medication, people gain an average of 0.4 kg per month. After 1.7 years, they regain their initial weight. Even more concerning: Weight gain after stopping medication is faster than after behavioral interventions (a difference of 0.3 kg/month). This article explains the latest findings – in a practical and evidence-based way.

What the meta-analysis shows

This study is a systematic review and meta-analysis. Think of a meta-analysis like a large puzzle: it pieces together many individual, small study images to create a large, meaningful overall picture. In this case, data from almost 10,000 people were analyzed to understand the course of body weight after discontinuing modern medications.

• Study type: Systematic review and meta-analysis (highest level of evidence).

• Data basis: 37 studies with a total of 63 intervention arms.

• Participants: n = 9,341 overweight or obese adults.

• Main result (weight): After discontinuing the medication, weight increased by an average of 0.4 kg per month (95% CI: 0.3–0.5).

• Time factor: It is predicted that the original starting weight will be fully regained after approximately 1.7 years (95% CI: 1.3–2.1).

• Comparison to lifestyle: Weight gain occurred significantly faster than after pure behavioral interventions (difference of +0.3 kg/month).

• Cardiometabolic markers: Blood pressure, blood sugar and blood lipids returned to baseline levels within approximately 1.4 years.

Mechanism: Why the weight gain after stopping medication?

Why does the weight come back so quickly? It's not due to a lack of discipline, but rather to profound biological adaptations. You can imagine it like a rubber band: The medication stretches the band (the weight) downwards. When you release it (stop taking the medication), the band springs back with energy.

• Loss of the satiety signal: GLP-1 agonists mimic a strong satiety hormone. If this signal is absent, hunger often returns with increased intensity ("rebound hunger").

• Hormonal counter-regulation: The body tries to protect its fat reserves. After weight loss, the hunger hormone ghrelin is often elevated, while the satiety hormone leptin is reduced.

• Adaptive thermogenesis: After a diet, the metabolism often works more efficiently. Without the metabolism-boosting effects of some medications, the body burns fewer calories at rest.

• Depletion of stores: Medications such as GLP-1 agonists also affect gastric emptying. If this normalizes, food can be consumed again more quickly.

• Loss of "food noise" suppression: Many patients report a "silence in their mind" regarding food while on medication. After discontinuing the medication, these constant thoughts about food often return intensely.

What does that mean for you? (Dosage & Strategy)

The data clearly show that obesity is a chronic disease, not a temporary phase that can be cured with a short "treatment". This means in practice:

• Long-term perspective: Assume that drug therapy will likely require long-term treatment, similar to high blood pressure.

• No abrupt discontinuation: If discontinuation is planned, it should be done gradually and under medical supervision ("tapering").

• Intensive support: The period after discontinuation is the most critical. Nutritional counseling and coaching are more important than ever during this time.

• Lifestyle as a foundation: Medication is a tool, not a replacement. A stable foundation of nutrition, exercise, and sleep is necessary to at least cushion the "rebound".

• Realistic expectations: Be aware that weight gain after stopping medication is biologically normal. Don't define success solely by the scale, but also by health markers.

For whom is this information particularly relevant?

These findings are not only important for patients, but also change the perspective on the entire treatment strategy.

• Current users: Individuals who are currently using GLP-1 agonists (e.g., semaglutide, tirzepatide) and are considering discontinuing them.

• Interested parties: People considering such therapy should take the need for long-term treatment into account when making their decision.

• Medical professionals: Doctors must inform patients before starting therapy about the high probability of relapse if the therapy is discontinued.

• Payers: The data underline that short-term approvals of these medications are often not medically sustainable.

• Responders: Especially people who have lost a lot of weight during therapy are often exposed to a stronger physiological pressure to regain weight.

Side effects & risks when discontinuing treatment

While stopping the medication is usually safe, the body reacts to the change. It's important to pay attention to these signals.

• Blood sugar fluctuations: In diabetics or prediabetics, blood sugar levels can rise rapidly again. Close monitoring is essential.

• Cravings: The sudden return of appetite can be perceived as overwhelming and lead to "binge eating".

• Psychological stress: The rapid recurrence can lead to frustration, shame, and depressive moods.

• Cardiometabolic risks: With weight gain, elevated blood pressure and worse blood lipid levels often return, which again increases the cardiovascular risk.

• Gastrointestinal tract: While the therapy often causes nausea, discontinuation can lead to altered digestion, as gastric emptying accelerates again.

Limitations of the meta-analysis

1. Limited long-term data: There have been few studies that followed participants for more than 2 years after discontinuation, so the very long-term course is still uncertain.

2. Drug heterogeneity: The analysis grouped together different drug classes (not only GLP-1, but also older substances), which could slightly limit the generalizability to specific new drugs.

3. Indirect comparison: The comparison between medication and behavioral interventions was indirect, as few studies directly compared both approaches "head-to-head" in the discontinuation scenario.

4. Linear assumption: The statistical models simplified the assumption of a linear progression of weight regain, although weight changes in reality often follow a wave-like or plateau-like pattern.

5. Risk of bias: Some of the included studies showed an increased "risk of bias", which could moderately affect the strength of the conclusions.

⚠ Important note:

This information is for general informational purposes only and does not constitute medical advice. Discontinuing weight-loss medication should always be discussed with your doctor. Stopping medication on your own can lead to health risks. Always consult a qualified healthcare professional if you have any health problems.

Sources

1. West S, Scragg J, Aveyard P, et al. (2026). Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ ; 392:bmj-2025-085304. DOI: 10.1136/bmj-2025-085304

2. Perreault L, et al. (2026). Lifestyle Intervention for Sustained Remission of Metabolic Syndrome. JAMA Internal Medicine ; 186(3):289-299. DOI: 10.1001/jamainternmed.2025.5900

3. Rubino D, et al. (2025). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA ; 325(14):1414-1425. DOI:10.1001/jama.2021.3224